Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…Abstract Number: 2525 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Background/Purpose: Guidelines recommend to treat newly diagnosed Early Rheumatoid Arthritis (ERA) with intensive treatment strategies using Methotrexate (MTX) or a combination of csDMARDs and a…Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Background/Purpose: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…Abstract Number: 1095 • 2016 ACR/ARHP Annual Meeting
Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin
Background/Purpose: Periarticular bone loss is a long known and early but yet insufficiently understood phenomenon in patients with rheumatoid arthritis. This study investigated whether autoimmunity…Abstract Number: 2545 • 2016 ACR/ARHP Annual Meeting
Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
Background/Purpose: The Disease Activity Score (DAS) and the European League Against Rheumatism (EULAR) response criteria are commonly used to describe disease activity in Rheumatoid Arthritis…Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting
Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…Abstract Number: 1198 • 2016 ACR/ARHP Annual Meeting
Gene Enrichment Analysis Identifies Active CD40-CD40L Signaling in Early and Established Rheumatoid Arthritis
Background/Purpose: CD40 and CD40L (CD154) are tumor necrosis factor (TNF) family members involved in the pathogenesis of various autoimmune diseases. While this pathway is active…Abstract Number: 2645 • 2016 ACR/ARHP Annual Meeting
Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials
Background/Purpose: The objective of this systematic review was to evaluate the clinical evidence on the efficacy of different drug regimens for the treatment of early…Abstract Number: 115 • 2016 ACR/ARHP Annual Meeting
Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Background/Purpose: Differences in access to care that influence the timing and quality of treatment interventions may create outcome inequities for Aboriginal patients with inflammatory arthritis.…Abstract Number: 1266 • 2016 ACR/ARHP Annual Meeting
Predictors of Radiographic Progression in Early Rheumatoid Arthritis Patients Treated By an Aggressive Treat-to-Target Regimen
Background/Purpose: With implementation of tight control strategies and defined treatment targets in rheumatoid arthritis (RA) care, a majority of early RA patients may reach remission…Abstract Number: 2987 • 2016 ACR/ARHP Annual Meeting
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…Abstract Number: 153 • 2016 ACR/ARHP Annual Meeting
Synovial Immunophenotype and Ultrasonography: A Contemporaneous Study of Different Compartments of the Knee Joint
Background/Purpose: Histological analysis of synovial tissue, despite being a reliable and accurate assessment for synovitis, is not routinely performed. Ultrasonography (US) is a fast, available…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 18
- Next Page »